Baylor College of Medicine

1. Novartis Pharmaceuticals Corporation $14,864,424 104 payments
2. Pfizer Inc. $14,570,271 479 payments
3. Merck Sharp & Dohme Corporation $6,313,129 72 payments
4. PTC Therapeutics, Inc. $4,455,699 216 payments
5. Genentech, Inc. $4,324,444 255 payments
6. Hoffmann-La Roche Limited $3,520,638 100 payments
7. AbbVie, Inc. $3,013,644 413 payments
8. Ucb SA $2,841,199 5 payments
9. Takeda Pharmaceuticals U.S.A., Inc. $2,589,186 593 payments
10. Abbott Laboratories $2,585,981 278 payments

1. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $7,653,058 65 payments
2. Epik-P2: A Phase II Double-Blind Study With An Upfront, 16-Week Randomized, Placebo-Controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (Byl719) in Pediatric and Adult Patients With Pik3ca-Related Overgrowth Spectrum (Pros) $5,120,973 10 payments
3. A Phase 3 Study of Eltrombopag VS Standard First Line Management for Newly Diagnosed Immune Thrombocytopenia Itp in Children $3,027,927 5 payments
4. Safety Efficacy of A Combination of Remdesivir Tocilizumab in Severe Covid 19 Pneumonia $3,017,335 46 payments
5. EPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with PIK3CA mutations, preceded by an explo $2,565,664 3 payments
6. EPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with PIK3CA mutations, preceded by an exploratory stage to assess the dose and early efficacy signal of alpelisib in these patients $1,996,133 2 payments
7. An Open-Label Trial to Address the Safety of the Smartflow Mr-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects $1,585,655 28 payments
8. Covacta Actemra Covid 19 Pneumonia Study $1,529,499 166 payments
9. The Microbiology and Clinical Outcomes of Moderate to Severe Acute Respiratory Infections in Hospitalized Adults After the Covid19 Pandemic May 11 2023 $1,516,254 5 payments
10. An Open-Label Trial to Address the Safety of the Smartflow Mr Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects $1,350,346 20 payments

1. Patient care $551,383 68 payments
2. Other $397,187 121 payments
3. Overhead $182,002 18 payments
4. Non-patient care $30,534 5 payments
5. Medical research writing or publication $24,300 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.